I-MAB Biopharma Co Ltd, a Shanghai-based biotech company focused on innovative biologics in immuno-oncology and autoimmune diseases, and Genexine Inc (KOSDAQ: 095700), a South Korea-listed clinical stage pharma company developing innovative biologics, have received approval from the China National Medical Products Administration (NMPA) for the Investigational New Drug (IND) application for TJ107 (HyLeukin), claimed to be the first and only long-acting recombinant human interleukin-7 (rhIL-7) globally to treat chemotherapy induced lymphopenia and cancer, it was reported on Friday.
The product is an immuno-oncology agent and includes an optimally engineered interleukin-7 (IL-7) molecule based on Genexine's proprietary hybrid Fc (hyFc) technology for half-life extension, with improved stability and ability to be developed. I-Mab has development and commercialisation rights to TJ107 (HyLeukin) in Greater China through an exclusive licensing agreement with Genexine that was agreed in December 2017.
Joan Shen, MD, PhD, president of R&D at I-Mab, said, 'We are pleased that the NMPA has given their greenlight to the IND filing, which is another significant development milestone in advancing our China Portfolio. The clinical potential of TJ107 (HyLeukin) has been recognised and endorsed by the regulatory authorities, since there is no approved treatment globally for lymphopenia, the unmet medical need is substantial.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca